Provider: Thomson Reuters Stock Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
R&I affirms Dainippon Sumitomo Pharma’s rating at "A" and rating outlook stable
Dainippon Sumitomo Pharma Co Ltd:Rating and Investment Information, Inc. (R&I) has affirmed the rating on the company at "A".The rating outlook is stable.
Latest Developments for Sumitomo Dainippon Pharma Co Ltd
- Dainippon Sumitomo Pharma Co Ltd to sell property and expects extraordinary profit for Q3 of FY 2015
- Dainippon Sumitomo Pharma Co Ltd expects extraordinary profit for Q2 of FY 2015
- Dainippon Sumitomo Pharma raises mid-year consolidated net profit outlook for FY 2015
- Dainippon Sumitomo Pharma raises consolidated full-year outlook for FY 2014
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this